Clinical trial
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV…
NCT00132002 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00132002 |
|---|---|
| Title | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer |
| Official title | Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | vorinostat, laboratory biomarker analysis |
| Enrollment | 14 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Aug 19, 2005 |
| Last update posted | Mar 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: